Avalo Therapeutics, Inc. (AVTX) — Revenue
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $59.0K | -86.6% |
| 2024 | $441.0K | -77.1% |
| 2023 | $1.92M | -89.3% |
| 2022 | $18.05M | +234.4% |
| 2021 | $5.40M | -19.4% |
| 2020 | $6.70M | -0.8% |
| 2019 | $6.75M | -4.0% |
| 2018 | $7.03M | -74.7% |
| 2017 | $27.81M | — |
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $59.0K | -86.6% |
| 2024 | $441.0K | -77.1% |
| 2023 | $1.92M | -89.3% |
| 2022 | $18.05M | +234.4% |
| 2021 | $5.40M | -19.4% |
| 2020 | $6.70M | -0.8% |
| 2019 | $6.75M | -4.0% |
| 2018 | $7.03M | -74.7% |
| 2017 | $27.81M | — |